Arthritis News – 1999

Based on the findings from ATTRACT (Anti-TNF trial in Rheumatoid Arthritis with Concomitant Therapy), the Food and Drug Administration (FDA) approved the use of Remicade with methotrexate for the treatment of rheumatoid arthritis.

ATTRACT is a double-blind, placebo-controlled, randomized clinical trial involving 428 patients at 34 clinical sites. At week 30, 50% of all patients treated with Remicade and methotrexate, compared to 20% of patients receiving methotrexate alone, achieved an ACR 20 response critieria.